Ocular Therapeutix (OCUL) Enterprise Value (2014 - 2026)

Ocular Therapeutix has reported Enterprise Value for 14 years, with the latest figure at -$598.6 million in Q2 2026.

• Enterprise Value for Q2 2026 came in at -$598.6 million, down 53.05% year-over-year; the trailing twelve-month figure through Jun 2026 was -$598.6 million (down 53.05% YoY), and the FY2025 annual result was -$737.1 million, down 87.98% from the prior year.
• Enterprise Value improved to -$598.6 million in Q2 2026, from -$666.7 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$66.6 million in Q2 2023 and troughed at -$737.1 million in Q4 2025.
• A 5-year average of -$322.5 million and a median of -$347.2 million in 2025 frame the typical range for Enterprise Value.
• The widest annual swing landed in 2023, when Enterprise Value jumped 50.49%; it then sank 590.16% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$102.3 million in 2022, then sank by 91.55% to -$196.0 million in 2023, then plunged by 100.1% to -$392.1 million in 2024, then slumped by 87.98% to -$737.1 million in 2025, then rose by 18.78% to -$598.6 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$598.6 million in Q2 2026, -$666.7 million in Q1 2026, and -$737.1 million in Q4 2025.